Purpose Of Review: 5-fluorouracil (5-FU) is one of the most common causes of cardiotoxicity associated with chemotherapy. The manifestations of 5-FU cardiotoxicity are diverse, and there are no established clinical guidelines addressing the diagnosis and management of this condition. Here we summarize the mechanistic and clinical data available to guide clinicians in caring for patients with suspected 5-FU cardiotoxicity.
View Article and Find Full Text PDFJ Cardiovasc Dev Dis
January 2021
Purpose Of Review: Both traditional and novel cancer therapies can cause cardiovascular toxicity in patients. In vivo models integrating both cardiovascular and cancer phenotypes allow for the study of on- and off-target mechanisms of toxicity arising from these agents. The zebrafish is the optimal whole organism model to screen for cardiotoxicity in a high throughput manner, while simultaneously assessing the role of cardiotoxicity pathways on the cancer therapy's antitumor effect.
View Article and Find Full Text PDFInt J Cardiol Heart Vasc
September 2019
Background: In 2015, the Ministry of Health (MINSA) of Peru inaugurated the first national center for electrophysiology studies in a public tertiary referral hospital with the purpose to provide healthcare access to the most underserved population. This study aims to describe the rate of success and complications of catheter ablation in this center since its inception, as well as the demographic characteristics of these patients.
Methods: This study is descriptive and retrospective.
Rev Peru Med Exp Salud Publica
July 2015
Objectives: To describe the findings of a year of epidemiological surveillance in pilot hospitals in Peru belonging to the diabetes surveillance (DS) system.
Materials And Methods: Cross-sectional study involving diabetic patients in the DS system from 18 hospitals during 2012. The DS database was assessed and epidemiological and laboratory variables were obtained including age, sex, type of diabetes, complications, comorbidity, microalbuminuria, fasting blood glucose and glycosylated hemoglobin (HbA1c) at two time points - at the time of enrollment and the last followup.